U.S. markets closed
  • S&P 500

    3,635.41
    +57.82 (+1.62%)
     
  • Dow 30

    30,046.24
    +454.97 (+1.54%)
     
  • Nasdaq

    12,036.79
    +156.15 (+1.31%)
     
  • Russell 2000

    1,853.53
    +35.23 (+1.94%)
     
  • Crude Oil

    44.89
    +1.83 (+4.25%)
     
  • Gold

    1,804.60
    -33.20 (-1.81%)
     
  • Silver

    23.25
    -0.38 (-1.60%)
     
  • EUR/USD

    1.1895
    +0.0049 (+0.42%)
     
  • 10-Yr Bond

    0.8820
    +0.0250 (+2.92%)
     
  • GBP/USD

    1.3361
    +0.0039 (+0.29%)
     
  • USD/JPY

    104.4570
    -0.0310 (-0.03%)
     
  • BTC-USD

    18,914.61
    +462.64 (+2.51%)
     
  • CMC Crypto 200

    375.53
    +5.78 (+1.56%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know

Zacks Equity Research
·3 min read

In the latest trading session, OPKO Health (OPK) closed at $4.30, marking a +0.7% move from the previous day. This move outpaced the S&P 500's daily gain of 0.35%. At the same time, the Dow lost 0.1%, and the tech-heavy Nasdaq gained 0.37%.

Coming into today, shares of the holding company with investments in pharmaceutical and diagnostics companies had gained 39.09% in the past month. In that same time, the Medical sector gained 0.51%, while the S&P 500 gained 4.32%.

Wall Street will be looking for positivity from OPK as it approaches its next earnings report date. This is expected to be October 29, 2020. The company is expected to report EPS of $0.04, up 136.36% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $375.30 million, up 64.03% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of $0.03 per share and revenue of $1.27 billion, which would represent changes of +107.32% and +41.26%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for OPK. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. OPK is currently a Zacks Rank #3 (Hold).

Investors should also note OPK's current valuation metrics, including its Forward P/E ratio of 128.1. This valuation marks a premium compared to its industry's average Forward P/E of 62.84.

We can also see that OPK currently has a PEG ratio of 10.68. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 4.01 at yesterday's closing price.

The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 176, which puts it in the bottom 31% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research